RxDoctor Payments Data

Gary Vitale, MD

Surgery · Louisville, KYNPI 1336128867

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $55,825 of the $62,646 with a category attached, or 89.1%. AbbVie accounts for 98.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $19,166 and has fallen 97.6% since, to $460 in 2025. Among surgery clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,646in general payments, 2019–2025

Across 165 payments — averaging $379.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$62K
  • Boston Scientific$498
  • W. L. Gore & Associates, Inc.$255
  • Pacira Pharmaceuticals Incorporated$125
  • Acera Surgical, Inc.$53
  • Olympus America Inc.$51
  • plus $93 from 4 others

What the payments were for

  • Speaking & faculty fees$55,82589%
  • Travel & lodging$1,7583%
  • Food & beverage$5,0638%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,646 in reported general payments places this provider in the 95th percentile of 377 surgery providers in Kentucky.

See all surgery providers in Kentucky

Medicare billing

Part B allowed, 2024
$123,281
Medicare patients
297
Services billed
908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase216$755,761
ZenpepLipase/Protease/Amylase19$70,280
LinzessLinaclotide14$7,849
Ursodiol74$7,642
Esomeprazole Magnesium116$2,613
Sucralfate123$2,534
Lubiprostone22$2,269
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates34$2,252
Pantoprazole Sodium63$303
Omeprazole24$282
Ondansetron Hcl13$237
Metoclopramide Hcl14$220
Promethazine Hcl31$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$61,572$763,610230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 377 surgery providers in Kentucky.

Other surgery in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →